KOSDAQBiotech & Pharma328130

Lunit

₩15,950▲ 0.82%2026-11-18 close
Market Cap
₩1.2T
Turnover
₩21B
Volume
1.3M
Shares out.
74.5M
PER
—
PBR
—
EPS
-₩1,494
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Lunit: Losses Narrow, Breakeven Still Ahead

Lunit cut its Q3 2026 operating loss to KRW 10.7 billion, down 50% year on year, but net losses attributable to controlling shareholders over the last four quarters keep breakeven as the central test.

  1. 1

    Q3 2026 revenue was KRW 22.2 billion, up 13.5% year on year, while the operating loss narrowed to KRW 10.7 billion from a year earlier.

  2. 2

    According to the company's November 12, 2026 announcement (preliminary), cash operating costs fell 25% year on year in Q3, the third straight quarterly decline, and nine-month revenue of KRW 67.98 billion was the highest since the company's founding.

  3. 3

    Net losses attributable to controlling shareholders over the last four quarters total KRW 102.9 billion, and the Q3 2026 figure widened even as the operating loss narrowed.

  4. 4

    Overseas revenue accounts for about 95% of sales, and North American subscription revenue in cancer screening is driving growth.

  5. 5

    The April 2026 rights offering drew 104.7% subscription from existing shareholders, so future cash flow improvement is now the key thing to track.

02

Business structure

Lunit develops AI software that analyzes medical images and supplies it to hospitals, screening centers and global pharmaceutical companies. The business is split into two segments, cancer screening and oncology.

Cancer screening centers on mammography reading solutions such as Lunit INSIGHT MMG and chest X-ray analysis solutions such as Lunit INSIGHT CXR, and its nine-month 2026 revenue was KRW 63.17 billion, up 20% year on year.

About 71% of this segment's revenue comes from North America, where the subsidiary Lunit International (formerly Volpara) supplies services on a subscription basis.

The oncology segment works with pharmaceutical companies around Lunit SCOPE, an AI-based biomarker analysis platform, and its nine-month revenue was KRW 4.81 billion, up 19% year on year.

The company says demand for Lunit SCOPE uIHC, an immunohistochemistry analysis solution, has grown as interest in antibody-drug conjugates (ADC) has increased.

Pharma collaboration projects built on Lunit SCOPE IO, a tumor microenvironment analysis solution, are also increasing, and this revenue has typically been concentrated in the fourth quarter. Overseas revenue reached KRW 64.27 billion in the first nine months of 2026, about 95% of the total.

Customers fall into three groups: medical institutions such as hospitals and screening centers, public bodies that run national screening programs, and global pharmaceutical companies.

Competition centers on other AI image-reading companies, and the company emphasizes a product mix that pairs reading AI with screening operation solutions.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩19.6B-₩21.6B−110.1%
2025Q4₩26.5B-₩19.6B−74.2%
2026Q1₩24B-₩13.6B−56.8%
2026Q2₩21.8B-₩15.4B−70.5%
2026Q3₩22.2B-₩10.7B−48.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩13.9B-₩50.7B-₩39.1B−365.3%−56.8%41.0%
2023₩25.1B-₩42.2B-₩36.8B−168.3%−15.7%14.0%
2024₩54.2B-₩67.7B-₩82.4B−124.9%−50.0%163.9%
2025₩83.1B-₩83.1B-₩47.4B−100.0%−34.5%169.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 13.9 billion in 2022 to KRW 25.1 billion in 2023 (up 80.9% year on year), KRW 54.2 billion in 2024 (up 116.0%) and KRW 83.1 billion in 2025 (up 53.4%), growing three years in a row from 2023 through 2025, with 2025 the largest year in the period.

Operating losses were KRW 50.7 billion in 2022, KRW 42.2 billion in 2023, KRW 67.7 billion in 2024 and KRW 83.1 billion in 2025, a loss in each of the four years from 2022 through 2025. The loss narrowed in 2023 but widened again in 2024 and 2025.

Because revenue grew quickly, the operating margin improved from -365.3% in 2022 to -168.3% in 2023, -124.9% in 2024 and -100.0% in 2025. Net losses attributable to controlling shareholders were KRW 39.1 billion in 2022, KRW 36.8 billion in 2023, KRW 82.4 billion in 2024 and KRW 47.4 billion in 2025.

Net loss including non-controlling interests was reported at the same amounts for each year. At the end of 2025, total equity was KRW 13.7 billion, all attributable to controlling shareholders, and total liabilities were KRW 23.3 billion, lifting the debt ratio to 169.2% from 163.9% in 2024 and 14.0% in 2023.

Operating cash flow was negative in every year, at -KRW 53 billion in 2022, -KRW 36.5 billion in 2023, -KRW 65.7 billion in 2024 and -KRW 55.2 billion in 2025.

Quarterly operating losses have run for five consecutive quarters from Q3 2025 through Q3 2026, and net income attributable to controlling shareholders turned into a net loss of KRW 32.4 billion in Q4 2025 from a profit of KRW 18.1 billion in Q3 2025.

Operating losses in Q1 to Q3 2026 were KRW 13.6 billion, KRW 15.4 billion and KRW 10.7 billion, while net losses attributable to controlling shareholders were KRW 17.8 billion, KRW 23.6 billion and KRW 29.1 billion.

The company announced on November 12, 2026 (preliminary) that cumulative revenue for the first three quarters of 2026 was KRW 67.98 billion, the highest since its founding.

05

Industry analysis

The medical imaging AI market is widening from image-reading support into running screening programs. In September 2026, Lunit said the Stockholm region of Sweden would adopt Lunit INSIGHT MMG, its AI mammography analysis solution, for breast cancer screening across the whole region.

In February 2026, Lunit won a contract for Malta's national breast cancer screening program, becoming the first EU member state case of this kind, and the company said the number of European countries running national screening with its solutions had risen to nine.

In the UK, it added GenesisCare UK, which operates cancer and diagnostic centers across the country, as a new customer. On the pharma side, interest in antibody-drug conjugates has lifted demand for immunohistochemistry analysis.

The company is structurally export-oriented, with overseas revenue at about 95% of sales, and its North American subscription base is cited as a point of differentiation.

Demand from the front end depends on expanding screening populations and the adoption of national screening systems, so the pace at which contract announcements accumulate is a signal of where the industry sits in its cycle.

Intensifying competition among AI imaging companies at home and abroad could also affect contract terms and pricing. The decline in the won-dollar exchange rate has worked as an external factor that reduces the won value of overseas revenue.

06

Outlook

In its November 12, 2026 announcement, the company said it would continue the shift of growing revenue while cutting costs through the fourth quarter and into 2027.

Pharma-related revenue has typically clustered in the fourth quarter, so how Q4 2026 revenue and operating loss move from Q3 2026 (revenue KRW 22.2 billion, operating loss KRW 10.7 billion) is the first checkpoint.

Dong-A's coverage noted that a breakeven would require securing a large oncology contract in the fourth quarter. On the pipeline side, the September 2026 win for region-wide breast cancer screening in Stockholm, Sweden is cited as an example of regional scaling.

On the funding side, the April 2026 rights offering drew 104.7% subscription from existing shareholders, and the proceeds were disclosed as planned for operations and R&D.

In the same month, the venture capital firm Atinum Investment took part in the offering, with a total investment of KRW 30 billion including management's purchase of subscription rights, according to the company's IR listings.

The Q4 2026 results are expected in early 2027, but the exact schedule should be confirmed through company disclosures. The 2026 annual business report is due by the end of March 2027, the statutory deadline, and it will set the annual operating cash flow and debt structure.

Whether the EBITDA loss reduction carries through to smaller operating and controlling-shareholder net losses is another point to watch.

07

Valuation

PER
—
PBR
—
ROE
-47.2%
EPS
-₩1,494
BPS
—
Dividend per share
₩0

Valuation should be read alongside the earnings trend. Net losses attributable to controlling shareholders have continued over the last four quarters, so the price-to-earnings ratio is not calculable. The dividend yield is effectively negligible, which leaves few shareholder-return metrics to assess.

Market capitalization sits well above total equity at the end of 2025, which means a large premium over book net assets. Market capitalization also far exceeds annual revenue. This picture could read differently if the operating loss keeps narrowing and cash outflows shrink.

Comparisons with the past trading band would need a time series that reflects share price changes. Over several years, the operating margin improved from -365.3% in 2022 to -100.0% in 2025, reducing the loss ratio, while the debt ratio stood at a high 169.2%.

Whether multiples are high or low relative to the industry average depends on differences in business stage and growth rates.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Cost structure is improving

Q3 2026 operating loss narrowed 50% year on year to KRW 10.7 billion. According to the company's November 12, 2026 announcement, cash operating costs fell 25% year on year, the third straight quarterly decline, and the EBITDA loss of KRW 3.5 billion was the smallest in 14 quarters. Bulls point to revenue growth and cost cuts happening together in every quarter.

North American subscription base

Cancer screening revenue for the first three quarters reached KRW 63.17 billion, up 20%, and North America accounted for 71% of that segment. Subscription services at Lunit International are cited as creating recurring revenue.

The September 2026 Stockholm region-wide breast screening win was described in press coverage as significant as a regional rollout.

Oncology and pharma collaboration

Oncology revenue for the first three quarters rose 19% to KRW 4.81 billion. The company says demand for Lunit SCOPE uIHC increased as interest in antibody-drug conjugates grew. With pharma collaborations increasing, whether new contracts appear in the fourth quarter is the next thing to check.

09

Bear factors

Losses and cash outflows persist

The operating loss narrowed, but the cumulative operating loss for the first three quarters of 2026 was KRW 39.6 billion (preliminary). Net losses attributable to controlling shareholders over the last four quarters total KRW 102.9 billion, and the Q3 2026 figure of KRW 29.1 billion was larger than Q2. Operating cash flow was KRW -55.2 billion in 2025 and negative in each year since 2022.

Balance sheet and funding needs

At the end of 2025, total equity was KRW 13.7 billion and total liabilities were KRW 23.3 billion, a debt ratio of 169.2%. The April 2026 rights offering drew 104.7% subscription, but if operating cash outflows continue, the need for further funding remains. Financial headroom will need to be confirmed through cash flows in coming quarters.

Overseas dependence and small oncology scale

Overseas revenue at about 95% of sales means currency moves feed directly into results. The company said the weaker dollar against the won reduced the won value of revenue.

Oncology revenue of KRW 4.81 billion is a small share of the total, and its 19% growth rate is close to screening's 20%, so some coverage questions whether its scale is large enough to serve as a new growth pillar.

10

Risk factors

FX exposure and overseas concentration

Overseas revenue at about 95% of sales means won-dollar moves flow directly into translated revenue and profit. The company said a stronger won reduced the won value of overseas revenue in Q3 2026. North America supplies 71% of cancer screening revenue, which adds dependence on a single market.

Capital raising and balance sheet

The April 2026 rights offering has closed, yet the debt ratio at the end of 2025 was 169.2%. Operating cash flow has been negative every year from 2022 to 2025, so any further fundraising will depend on how fast cash leaves the business.

Pharma revenue seasonality and contract timing

Pharma-related revenue has typically clustered in the fourth quarter, so quarterly results can swing with contract timing. Oncology revenue for the first three quarters of 2026 was KRW 4.81 billion, a small base where the timing of a large contract can significantly shape quarterly results. Dong-A's coverage said a breakeven would need a large contract in the fourth quarter.

11

What to watch next

  1. December 2026

    Whether large Lunit SCOPE-related contracts are confirmed in the fourth quarter, when pharma collaboration revenue typically concentrates, is the checkpoint. Also watch how Q4 revenue moves from the KRW 22.2 billion recorded in Q3.

  2. End of December 2026

    Check whether the three-quarter streak of declining cash operating costs continues in Q4. A stall in cost reductions would change the durability of the narrowing operating loss.

  3. Early 2027 (schedule not yet set)

    The Q4 2026 results should show what drives the gap between operating loss and net loss attributable to controlling shareholders. Whether Q3's pattern of a narrowing operating loss alongside a wider net loss continues is the key question.

  4. End of March 2027

    The 2026 annual business report will confirm full-year operating cash flow, total equity and total liabilities. It is the basis for judging how the balance sheet has changed since the April 2026 rights offering.

  5. Ad hoc disclosures from November 2026

    Watch whether national screening and hospital contract announcements in Europe and North America continue. A rising number of national-level programs would indicate a broader base for cancer screening revenue.

12

Overall view

In Q3 2026, Lunit recorded revenue of KRW 22.2 billion and an operating loss of KRW 10.7 billion, growing sales while narrowing losses.

According to the company's announcement, cumulative revenue for the first three quarters of 2026 of KRW 67.98 billion was the highest since its founding, cash operating costs fell for three straight quarters, and the EBITDA loss was the smallest in 14 quarters.

On the other side, the Q3 2026 net loss attributable to controlling shareholders widened to KRW 29.1 billion from Q2, and the four-quarter total is KRW 102.9 billion.

Operating cash flow was negative in each year from 2022 to 2025, and the balance sheet, with total equity of KRW 13.7 billion, total liabilities of KRW 23.3 billion and a debt ratio of 169.2%, will need to be tracked through coming quarterly cash flows.

Overseas revenue at about 95% of sales supports growth but also exposes the company to currency swings. The next checkpoints are Q4 2026 pharma collaboration revenue and the direction of operating results, along with annual cash flow in the 2026 business report. This report is provided for information only and does not contain an investment opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. venturesquare.net
  2. dhilbo.co.kr
  3. kr.investing.com
  4. wowtale.net
  5. rapportian.com
  6. daily.hankooki.com
  7. widedaily.com
  8. businesspost.co.kr
  9. hitnews.co.kr
  10. m.irgo.co.kr
  11. view.asiae.co.kr
  12. markets.hankyung.com
  13. theguru.co.kr
  14. topstarnews.net
  15. digitaltoday.co.kr
  16. wowtale.net

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis